Allopurinol/lesinurad

Drug Profile

Allopurinol/lesinurad

Alternative Names: DUZALLO; Lesinurad allopurinol FDC; Lesinurad/allopurinol; lesinurad/allopurinol 200/300 FDC; RDEA-594/allopurinol; Zurampic/Allopurinol FDC

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; Grunenthal
  • Class Acetic acids; Antigouts; Cyclopropanes; Naphthalenes; Purines; Small molecules; Sulfides; Triazoles; Urologics
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Gout

Most Recent Events

  • 01 Sep 2017 Chemical structure information added
  • 21 Aug 2017 Registered for Gout in USA (PO)
  • 21 Aug 2017 Allopurinol/lesinurad has a boxed warning for risk of Acute renal failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top